Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia
Status:
Active, not recruiting
Trial end date:
2021-12-05
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of pevonedistat when given together
with decitabine in treating patients with high risk acute myeloid leukemia. Pevonedistat and
decitabine may stop the growth of cancer cells by blocking some of the enzymes need for cell
growth.